Amarin Corp Plc (AMRN)

[FesteringPus]

Amarin

On Thursday, shares in Dublin, Ireland-based Amarin Corp. PLC recorded a trading volume of 1.39 million shares. The stock ended the day at $3.16, which was 1.56% lower from the prior session. The Company's shares have gained 0.96% in the last one month, 44.29% over the previous three months, and 67.20% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 4.98% and 52.35%, respectively. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 54.75.

As per notes filed with the SEC, on September 22(nd) and 23(rd) , 2016, Amarin, through its subsidiary Amarin Pharmaceuticals Ireland Limited, received paragraph IV certifications from Roxane Laboratories, Inc. and Dr. Reddy's Laboratories, Inc., respectively, advising Amarin that such companies have filed abbreviated new drug applications with the U.S. Food and Drug Administration that seek regulatory approval for generic versions of Vascepa (icosapent ethyl) capsules.

On October 5(th) , 2016, research firm Cantor Fitzgerald initiated a 'Buy' rating on the Company's stock, issuing a target price of $6 per share. The free research report on AMRN is available at:

http://stock-callers.com/registration/?symbol=AMRN